Today we’re showcasing ten of the most recent oncology-related articles posted recently across medical journals. The articles come from sources such as Perioperative Medicine, the Journal of Translational Medicine, and more. They range in focus from discussing cancer types like breast cancer and NSCLC, to bigger-picture topics like cancer disparities and enhanced cancer screenings in developing countries.

The following ten articles are presented in no particular order, and all were published in September of 2025.

The Impact of Sugammadex Versus Neostigmine Reversal on Return to Intended Oncological Therapy-related Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study

  • Perioperative Medicine, September 2025
  • Description: Early return to intended oncological therapy (RIOT) after cancer resection is a determinant for long-term oncological outcomes. Sugammadex is increasingly used to reverse the muscle relaxant effect of rocuronium during general anesthesia. It has been shown to improve early postoperative outcomes, but its impact on RIOT is unknown. This study tested the hypothesis that the administration of sugammadex during mastectomy for nonmetastatic breast cancer resection would be associated with better RIOT-related outcomes compared with neostigmine.
  • Summary
  • Full Text

Inflammatory Mitochondrial Signalling and Viral Mimicry in Cancer

  • Journal of Translational Medicine, September 2025
  • Description: Here, [researchers] critically discuss the molecular mechanisms through which the mitochondria-dependent cGAS-STING and MAVS pathways enable viral mimicry as elicited by the re-activation of TEs in neoplastic cells, as [the researchers] comment on the therapeutic potential of using epigenetic modifiers to harness these mechanisms in support of restored ICIs sensitivity across cancer types.
  • Summary
  • Full Text

Global Scoring Method of Ki67 Immunohistochemistry in Breast Cancer Demonstrates Improved Concordance Using Real-World Multi-institutional Data

  • Breast Cancer Research (BCR), September 2025
  • Description: Here, [researchers] present the first real-world data on the variability and impact of Ki67 scores on clinical decision-making in breast cancer when using hotspot scoring and after implementing IKWG global scoring method in clinical practice.
  • Summary
  • Full Text

Integrating Proteomics and Bioinformatics for the Identification of Breast Cancer Biomarkers Interacting with Telomeric G-quadruplex

  • Cancer Cell International, September 2025
  • Description: The identification of reliable biomarkers is essential for improving breast cancer (BC) detection, prognosis, and treatment. This study explores a human telomeric G-quadruplex (G4) model, tel, functionalized on Controlled Pore Glass (CPG) support, as a novel biomarker discovery tool.
  • Summary
  • Full Text

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response in Non-small Cell Lung Cancer (HAMMER-NSCLC)

  • BMC Cancer, September 2025
  • Description: Anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) immunotherapy promotes systemic anti-tumor immunity through expanding neoantigen-specific CD8 + T cells, but it is less effective in patients with liver metastases. Nearly 20% of non-small cell lung cancer (NSCLC) patients develop liver metastases, and these patients are characterized by fewer and less active effector T cells. Preclinical work has shown that liver metastases cause systemic immunosuppression through siphoning neoantigen-specific CD8 + T cells from systemic circulation with subsequent macrophage-mediated intrahepatic death. In preclinical models, liver metastasis-directed radiotherapy can reverse this systemic immunosuppression and sensitize tumors to anti-PD-(L)1 therapy. However, it is unknown whether liver metastasis-directed stereotactic ablative radiotherapy (liver SABR) can sensitize tumors to anti-PD-(L)1 in human NSCLC.
  • Summary
  • Full Text

Development and Validation of a Methylation-specific Droplet Digital PCR Multiplex for Lung Cancer Detection

  • Scientific Reports, September 2025
  • Description: In this study, [researchers] developed and validated a methylation-specific droplet digital PCR (ddPCR) multiplex assay with five tumour-specific methylation markers identified by in silico analysis for lung cancer detection across various clinical settings. The performance of the ddPCR multiplex was validated in tissue and plasma in cohorts of healthy controls and patients with both non-metastatic and metastatic disease by examining sensitivity, specificity, and marker dynamics.
  • Summary
  • Full Text

Cancer Disparities: Projection, COVID-19, and Scenario-based Diagnosis Delay Impact

  • PloS One, September 2025
  • Description: There has been limited research on how disparities in cancer mortality may evolve in the future, although relevant socio-economic and regional disparities in cancer risk are well-documented. [Researchers] studied future trends in breast cancer (BC) and lung cancer (LC) mortality up to 2036 across affluent and deprived communities in nine regions of England, motivated by the distinct socio-economic patterns and burden of these cancer types.
  • Summary
  • Full Text

Study Protocol for a Randomized Controlled Clinical Trial of a Multifaceted Cognitive Training Program Using Video Games in Childhood Cancer Survivors

  • PloS One, September 2025
  • Description: This randomized controlled trial aims to evaluate the efficacy of a cognitive training program using video games in improving neuropsychological, neurological, immunological, and inflammatory parameters in childhood cancer survivors. This study will recruit 56 patients aged 8-17 years who have completed cancer treatment 1-8 years prior to enrollment. Participants will be randomized to either the video game intervention or waiting group.
  • Summary
  • Full Text

Urinary Detection of High-risk HPV DNA to Enhance Cervical Cancer Screening in Developing Countries

  • Microbiology Spectrum, September 2025
  • Description: This study highlights the potential of the hrHPV ReadyMix qPCR Kit to enhance cervical cancer screening, offering valuable insights for future interventions.
  • Summary
  • Full Text

Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study

  • Cancer Epidemiology, Biomarkers, & Prevention, September 2025
  • Description: Coding changes in disease definitions have influenced trends in bladder cancer epidemiologic outcomes in registries. The Surveillance, Epidemiology, and End Results (SEER) Program introduced a harmonized staging variable (available from the SEER Program upon request) for long-term trend analysis. This study analyzes trends in bladder cancer incidence using the harmonized staging variable.
  • Summary
  • Full Text

Look forward to more journal-focused topics in the coming weeks. 

Sign up for alerts and stay informed on the latest published articles and guidelines.

Copyright © 2025 Guideline Central, all rights reserved.